Announced on the sidelines of the DistinctPRO Diabetes Innovation Summit 2026 in Dubai, the initiative supports broader regional access to advanced diabetes technologies through expanded healthcare professional training and education

Dubai, United Arab Emirates, February 02, 2026: Imperial College London Diabetes & Endocrine Centre (ICLDEC), part of M42’s outpatient care portfolio, and Medtronic, a global healthcare technology company, have signed a Memorandum of Understanding (MoU) to formalise a strategic collaboration to establish a Centre of Reference (COR) for automated insulin delivery (AID) in the Middle East. The agreement was signedduring the DistinctPRO Diabetes Innovation Summit 2026, held in Dubai.

The collaboration is designed to strengthen regional capabilities in insulin pump therapy and automated insulin delivery through structured clinical collaboration, shared best practices, and professional education. The COR will support the development of care pathways, and facilitate knowledge exchange, and build long-term capacity for advanced diabetes and metabolic care across the regional healthcare ecosystem.

Diabetes remains a major health challenge across the Middle East and North Africa, according to the International Diabetes Federation[1].Recent updates to the American Diabetes Association’s 2006 Standards of Care have reinforced the role of automated insulin delivery systems in type 1 diabetes and strengthened recommendations for insulin pump use in selected people with type 2 diabetes.

Dr. Mai Ahmed Al Jaber, Chief Executive Officer, Outpatient Care, M42, said: “Becoming a Centre of Reference for Automated Insulin Delivery reflects ICLDEC’s long-term commitment to advancing diabetes care through innovation, education, and collaboration. Our partnership with Medtronic underscores a shared focus on developing practical, scalable models that strengthen care delivery and support improved outcomes for people living with diabetes across the region and beyond.”

Hülya Tiner, Vice President for Strategic Marketing for Medtronic in the EurAsia region said: At Medtronic, we aim to improve outcomes for people living with diabetes by making innovative technologies more accessible. Partnering with ICLDEC to establish a Center of Reference for Automated Insulin Delivery strengthens our commitment to expanding access to proven, intelligent insulin delivery solutions in the Middle East. By combining our global leadership with ICLDEC’s regional expertise, we are creating a powerful platform to support clinicians and accelerate personalised diabetes care across the region.

The MoU was announced during the DistinctPRO Diabetes Innovation Summit 2026, a Dubai Health Authority–accredited and International Diabetes Federation–endorsed forum, now in its fourth edition. The two-day summit brought together 150 clinicians, researchers, and healthcare leaders from the Middle East, Central and Eastern Europe, Australia, and other international markets to examine how innovation and collaboration are shaping the future of personalised diabetes care.

DistinctPRO 2026 featured a curated scientific programme developed by a joint ICLDEC-Medtronic committee, with sessions spanning automated insulin delivery, time-in-range optimisation, AI-enabled clinical decision-making, digital health platforms, and technology-enabled care for special populations. Through plenaries, panel discussions, and masterclasses, participants explored the practical application of innovation in diverse clinical settings.

Hosted at the Hilton Dubai Al Habtoor City, the summit highlighted Dubai’s role as a global convening location for diabetes innovation, while reinforcing ICLDEC’s position as a regional and international centre for cutting-edge diabetes technology, research, and education. The event reflected a shared commitment by ICLDEC and Medtronic to support the continued evolution of personalised, data-driven care models that deliver meaningful value for people living with diabetes, healthcare systems, and wider communities.

– ENDS –

About the Imperial College London Diabetes & Endocrine Centre

Imperial College London Diabetes & Endocrine Centre (ICLDEC), an M42 company, is a state-of-the-art outpatient facility that specialises in treatment, research, training, and public health awareness for diabetes and endocrine-related health conditions. Over the last two decades, the Centre has gained international renown for its holistic approach to the treatment of diabetes and related complications that enables patients to receive the full spectrum of care they need in one place.

With more than 70 diabetes professionals and endocrinologists under one roof, Imperial College London Diabetes & Endocrine Centre offers best-in-class medical attention from first diagnosis to disease management across 11 specialist practice areas including adult and paediatric endocrinology, treatment of metabolic and electrolyte disorders, pre- and post-bariatric surgery care, heart disease prevention, nutritional advice, diabetes education services, ophthalmology, nephrology, and podiatry.

ICLDEC was established in 2006 in Abu Dhabi by Mubadala in partnership with the UK’s Imperial College London to address the growing demand for diabetes care in the UAE. The centre now operates four branches across Abu Dhabi, Al Dhafra and Al Ain, touching the lives of more than one million people through patient-centric programmes and public health initiatives. In 2007, ICLDEC launched Diabetes. Knowledge. Action, now the longest running public health awareness campaign in the country. The initiative promotes an active lifestyle through an ongoing calendar of events for the whole community.

ICLDEC holds the Joint Commission International (JCI) Clinical Care Program Certification in Outpatient Diabetes Management and JCI Accreditation for Ambulatory Care.

For more information, please visit www.icldec.ae

About M42

M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.

Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.

About the Diabetes Business at Medtronic

Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We’ve pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.